NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD
302.46
-1.54 (-0.51%)
The current stock price of ALNY is 302.46 USD. In the past month the price increased by 11.94%. In the past year, price increased by 88.58%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.45 | 334.73B | ||
AMGN | AMGEN INC | 14.13 | 157.78B | ||
GILD | GILEAD SCIENCES INC | 14.22 | 136.94B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.95B | ||
REGN | REGENERON PHARMACEUTICALS | 11.82 | 56.53B | ||
ARGX | ARGENX SE - ADR | 100.08 | 35.14B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.74 | 28.50B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
NTRA | NATERA INC | N/A | 22.56B | ||
BIIB | BIOGEN INC | 8.56 | 19.85B | ||
INSM | INSMED INC | N/A | 16.56B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.40B |
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142 US
CEO: John M. Maraganore
Employees: 2230
Phone: 16175518200
The current stock price of ALNY is 302.46 USD. The price decreased by -0.51% in the last trading session.
The exchange symbol of ALNYLAM PHARMACEUTICALS INC is ALNY and it is listed on the Nasdaq exchange.
ALNY stock is listed on the Nasdaq exchange.
39 analysts have analysed ALNY and the average price target is 330.33 USD. This implies a price increase of 9.22% is expected in the next year compared to the current price of 302.46. Check the ALNYLAM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 39.44B USD. This makes ALNY a Large Cap stock.
ALNYLAM PHARMACEUTICALS INC (ALNY) currently has 2230 employees.
ALNYLAM PHARMACEUTICALS INC (ALNY) has a support level at 285.55 and a resistance level at 304.57. Check the full technical report for a detailed analysis of ALNY support and resistance levels.
The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 28.41% in the next year. Check the estimates tab for more information on the ALNY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALNY does not pay a dividend.
ALNYLAM PHARMACEUTICALS INC (ALNY) will report earnings on 2025-07-30, before the market open.
ALNYLAM PHARMACEUTICALS INC (ALNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.09).
The outstanding short interest for ALNYLAM PHARMACEUTICALS INC (ALNY) is 2.94% of its float. Check the ownership tab for more information on the ALNY short interest.
ChartMill assigns a technical rating of 10 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 95.12% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ALNY. The financial health of ALNY is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 22.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -6.4% | ||
ROE | -233.64% | ||
Debt/Equity | 8.88 |
ChartMill assigns a Buy % Consensus number of 78% to ALNY. The Buy consensus is the average rating of analysts ratings from 39 analysts.
For the next year, analysts expect an EPS growth of 23.16% and a revenue growth 28.41% for ALNY